ALNY

Business Context and Reporting Period

Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2006
Business Overview: Alnylam is a biopharmaceutical company developing therapeutics based on RNA interference (RNAi) technology. The company has not yet received regulatory approval for any products and relies on strategic alliances (notably with Novartis and Merck) and equity financing to fund operations. As of March 31, 2006, the company had an accumulated deficit of $114.8 million.

Key Financial Metrics

Note: Total debt includes current portion ($2,006) and long-term portion ($5,320) as of March 31, 2006.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 248% to $5.7 million, driven primarily by $5.2 million in revenue recognized from the Novartis collaboration (up from $0 in Q1 2005). Revenue from Merck collaborations decreased to $0.3 million from $1.4 million due to the suspension of the AMD program.
• Expense Increase: Total operating expenses rose 86% to $15.5 million. R&D expenses more than doubled (122% increase) due to clinical trial costs for the RSV program and the adoption of SFAS 123R (stock-based compensation). G&A expenses increased 21%, largely due to higher stock-based compensation.
• Liquidity Improvement: Cash and cash equivalents increased significantly from $15.8 million to $56.8 million. This was primarily due to $62.2 million in net proceeds from a public offering of common stock completed in January 2006.
• Stock-Based Compensation: The adoption of SFAS 123R on January 1, 2006, resulted in a significant increase in non-cash stock-based compensation expense ($2.4 million in Q1 2006 vs. $0.5 million in Q1 2005).

Outlook, Risks, and Management Commentary

• Capital Resources: Management believes existing resources, combined with expected cash from alliances, are sufficient to fund operations beyond the end of 2007. However, the company expects to incur significant additional losses as it advances clinical trials.
• Development Pipeline: The company initiated human clinical trials for ALN-RSV01 (RSV treatment) in December 2005, with results released in May 2006 showing the drug was safe and well-tolerated. An IND for a pandemic flu therapeutic is expected by the end of 2006.
• Strategic Alliances: The company relies heavily on collaborations with Novartis (broad alliance and pandemic flu) and Merck (technology and ocular diseases) for funding and commercialization. Novartis holds approximately 19.9% of the company's stock.
• Risks:
  • Technology Risk: RNAi is an unproven technology; no RNAi therapeutics have received regulatory approval.
  • Patent Litigation: Key patents (Kreutzer-Limmer series) are subject to opposition proceedings in the European and Australian Patent Offices, which could invalidate them.
  • Financing: The company will require substantial additional funds for future development. Failure to secure funding could force curtailment of programs.
  • Regulatory: The FDA has not established definitive policies for RNAi drugs, creating uncertainty in the approval process.

Investor Verification Checklist

• Novartis Collaboration Terms: Verify the specific milestone triggers and revenue recognition schedules under the Novartis agreements, as they constitute the majority of current revenue.
• Patent Status: Monitor the outcome of the opposition proceedings against the Kreutzer-Limmer patents in Europe and Australia, as these are critical to the company's IP portfolio.
• Cash Burn Rate: Assess the sustainability of the current cash position ($132.3 million in liquid assets) against the projected increase in R&D spending for clinical trials.
• Stock-Based Compensation Impact: Review future dilution risks associated with the company's stock option plans and the ongoing expense impact of SFAS 123R.
• Clinical Trial Progress: Track the progression of the ALN-RSV01 program and the timeline for the pandemic flu IND submission.